Literature DB >> 3191600

Amiloride. Antiarrhythmic and electrophysiological activity in the dog.

H J Duff1, W M Lester, M Rahmberg.   

Abstract

Amiloride, a widely used diuretic, has multiple pharmacological actions, including inhibition of the sodium-hydronium ion and the sodium-calcium exchanger in heart. In terms of cardiac electrophysiology, amiloride prolongs action potential duration without alteration in upstroke velocity of phase 0 in Purkinje fibers. The antiarrhythmic efficacy of amiloride was assessed in a model of inducible sustained ventricular tachyarrhythmias in 16 dogs late after 2-hour occlusion-reperfusion of the left anterior descending coronary artery. Sixteen animals were studied: Four were randomly assigned to placebo, and 12 were assigned to amiloride treatment. Prolonged loading and maintenance infusions were designed to produce amiloride concentrations over the range achievable in humans. Animals were chronically instrumented to allow electrophysiological measures of conduction and refractoriness in the left ventricular infarct and border zones. Of the 12 animals treated with amiloride, six responded with inability to induce ventricular tachyarrhythmias, whereas of the four animals treated with placebo, none responded. The mean infarct size of the six animals responding to amiloride (12 +/- 5%) was significantly less than that of the six animals not responding to amiloride (20 +/- 8%). Overall, the only electrophysiological effect of amiloride observed in this study was prolongation of border zone ventricular refractoriness. This electrophysiological effect was accentuated in animals responding to amiloride. In addition, when animals were subdivided into responders, partial responders, or nonresponders, the border zone repolarization time was prolonged in responders and partial responders, whereas this measure shortened in nonresponding animals. Amiloride has antiarrhythmic activity in the suppression of sustained ventricular tachyarrhythmias in this postinfarction model.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3191600     DOI: 10.1161/01.cir.78.6.1469

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  8 in total

Review 1.  A prolonged QTc interval. Is it an important effect of antiarrhythmic drugs?

Authors:  F A Fish; D M Roden
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Nov-Dec

Review 2.  Role of the sodium-hydrogen exchanger in ischemia-reperfusion injury in diabetes.

Authors:  D P Goel; G N Pierce
Journal:  J Thromb Thrombolysis       Date:  1999-07       Impact factor: 2.300

Review 3.  Clinical potential of sodium-calcium exchanger inhibitors as antiarrhythmic agents.

Authors:  Steven M Pogwizd
Journal:  Drugs       Date:  2003       Impact factor: 9.546

4.  Modulation of KCNQ1 alternative splicing regulates cardiac IKs and action potential repolarization.

Authors:  Hsiang-Chun Lee; Yoram Rudy; Phd Po-Yuan; Sheng-Hsiung Sheu; Jan-Gowth Chang; Jianmin Cui
Journal:  Heart Rhythm       Date:  2013-04-19       Impact factor: 6.343

5.  Na+/H+ exchanger and reperfusion-induced ventricular arrhythmias in isolated perfused heart: possible role of amiloride.

Authors:  S Mochizuki; S Seki; M Ejima; T Onodera; M Taniguchi; S Ishikawa
Journal:  Mol Cell Biochem       Date:  1993-02-17       Impact factor: 3.396

6.  Equal reduction in infarct size by ethylisopropyl-amiloride pretreatment and ischemic preconditioning in the in situ rabbit heart.

Authors:  J Munch-Ellingsen; J E Løkebø; E Bugge; K Ytrehus
Journal:  Mol Cell Biochem       Date:  1998-09       Impact factor: 3.396

Review 7.  Na+/H+ exchange and its inhibition in cardiac ischemia and reperfusion.

Authors:  W Scholz; U Albus
Journal:  Basic Res Cardiol       Date:  1993 Sep-Oct       Impact factor: 17.165

8.  Effects of the potassium-sparing diuretic amiloride on chemotherapy response in canine osteosarcoma cells.

Authors:  Andrew C Poon; Jordon M Inkol; Anita K Luu; Anthony J Mutsaers
Journal:  J Vet Intern Med       Date:  2018-12-17       Impact factor: 3.333

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.